Cervical Cancer

(asked on 30th April 2019) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help ensure the approval of the use of Pembrolizumab for the treatment of cervical cancer given in line with its usage in the Republic of Ireland and the USA; and when that drug will be made available to people with cervical cancer.


Answered by
Seema Kennedy Portrait
Seema Kennedy
This question was answered on 7th May 2019

Pembrolizumab (Keytruda) was licensed on 12 June 2018 by the United States Food and Drug Administration for use in patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

However, pembrolizumab is not licensed for the treatment of cervical cancer in the United Kingdom or in the European Union. To obtain a licence for this indication, the Marketing Authorisation Holder of Keytruda (Merck Sharp & Dohme B.V.) would need to submit an ‘extension of indication’ application to the European Medicines Agency including evidence of safety and efficacy.

Reticulating Splines